[Technology and Achievements] Technology of Release Control Formulations (Sustained Release Granules)
By combining two types of enteric-coated granules, we achieve longer exposure! It has received high praise from clinical settings.
Our company has achieved a formulation that combines two types of enteric-coated pellets, one for immediate release (IR) and the other for delayed release (DDR), to attain a longer effective plasma concentration for clinical purposes. This technology is currently applied to capsule formulations sold domestically and has received high praise from clinical settings. We respond to all requests regarding CMC from the early stages of development to application. Please feel free to contact us when needed. 【Features】 ■ Achieves longer exposure by combining two types of enteric-coated pellets ■ Releases the active ingredient faster under neutral conditions than under acidic conditions, maintaining high plasma concentration ■ Applicable to oral morphine extended-release formulations *For more details, please refer to the PDF materials or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Our company is a pharmaceutical CMC research and development contract company that spun out from the CMC research division of Takeda Pharmaceutical Company Limited in July 2017. We support excellent pharmaceutical development as experts in CMC research. Our research team consists of experts with extensive experience and achievements in process chemistry, formulation research and development, and analytical testing development related to CMC research. We provide high-level services and solutions tailored to our customers' needs across each process from the early stages of pharmaceutical development to application, while flexibly collaborating. We have established a collaborative system with partner companies, enabling us to offer a one-stop service. Please utilize us as a platform for your pharmaceutical development.
![[Research Material] Global Market for Wound Care Biologics](https://image.mono.ipros.com/public/product/image/800/2001456551/IPROS88830835330865397375.jpeg?w=280&h=280)
